Sun Pharma shines on getting USFDA’s nod for supplemental biologics license application for ‘ILUMYA’
Mumbai, October 30 (Udaipur Kiran): Sun Pharmaceutical Industries is currently trading at Rs. 1795.05, up by 32.10 points or 1.82% from its previous closing of Rs. 1762.95 on the BSE.
The scrip opened at Rs. 1762.95 and has touched a high and low of Rs. 1804.05 and Rs. 1762.95 respectively. So far 31452 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 2047.55 on 31-Jul-2026 and a 52 week low of Rs. 1583.60 on 29-Jan-2026.
Last one week high and low of the scrip stood at Rs. 1,804.05 and Rs. 1725.65 respectively. The current market cap of the company is Rs. 430260.74 crore.
The promoters holding in the company stood at 52.68%, while Institutions and Non-Institutions held 36.63% and 10.70% respectively.
Sun Pharmaceutical Industries has received the U.S. Food and Drug Administration’s (USFDA) approval for its the supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA). Around 2.4 million Americans live with psoriatic arthritis, which can cause joint pain, swelling and stiffness that may lead to permanent joint damage. The approval expands the use of ILUMYA, an IL-23 inhibitor approved by the USFDA in 2018 for the treatment of adults with moderateto-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
The approval is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies, which evaluated the efficacy and safety of ILUMYA after only two doses at 24 weeks in adult patients with active psoriatic arthritis. Safety data in the studies was consistent with the well-documented safety profile of ILUMYA. No new safety signals were identified in the INSPIRE-1 and INSPIRE-2 studies. ILUMYA may increase the risk of infection. Patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment.
Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and Active Pharmaceutical ingredients (APIs).
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.